

Cross-Cultural Adaptation, Validation, and Reliability of the Indonesian Version of Kidney Disease and Quality of Life (The KDQOL-SF™ v1.3) Instrument

Nita Syamsiah¹, Faridah Mohd Said², Datin Hafizah Che Hassan³, Uun Nurjanah⁴

¹Departement of Nursing Sekolah tinggi Ilmu Kesehatan Horizon Karawang, Indonesia

^{3,4}Faculty of Nursing, Lincoln University College, Malaysia

⁵Departement of Nursing Sekolah tinggi Ilmu Kesehatan Kharisma, Indonesia



Jurnal Keperawatan Komprehensif
(Comprehensive Nursing Journal)

Volume 11 (2), 208-220
<https://doi.org/10.33755/jkk.v11i2>

Article info

Received : March 26, 2025
Revised : April 18, 2025
Accepted : April 27, 2025
Published : April 30, 2025

Corresponding author

Nita Syamsiah*

Departement of Nursing Sekolah Tinggi
Ilmu Kesehatan Horizon Karawang,
Indonesia

Jl. Pangkal Perjuangan By Pass No.KM.1,
Tanjungpura, Kec. Karawang Bar.,
Karawang, Jawa Barat 41316
Telepon: 0811-8454-800
e-mail : syamsiahnita4@gmail.com

Citation

Syamsiah N, Said FM, Che Hassan D,
Nurjanah U. Cross-cultural adaptation,
validation, and reliability of the Indonesian
version of Kidney Disease and Quality of
Life (the KDQOL-SF™ v1.3) instrument.
Jurnal Keperawatan Komprehensif.
2025;11(2):208-220.

Website

<https://journal.stikep-pnnijabar.ac.id/jkk>

This is an **Open Access** article distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0
International License



p-ISSN : [2354 8428](#)
e-ISSN: [2598 8727](#)

Abstract

Background: The Kidney Disease and Quality of Life Short Form (KDQOL-SF™ v1.3) was specifically developed to assess quality of life in individuals with kidney disease, including those not yet requiring dialysis. With the increasing burden of chronic kidney disease (CKD) in Indonesia, there is a need for culturally adapted and psychometrically sound instruments.

Objective: This study aimed to adapt, validate, and evaluate the reliability of the Indonesian version of the KDQOL-SF™ v1.3 among hemodialysis patients.

Methods: The KDQOL-SF™ v1.3 was adapted for cultural use by following international guidelines, including forward and backward translation, expert review, and interviews with patients. A total of 190 hemodialysis patients took part in the study. Construct validity was tested using factor analysis, and convergent validity was checked by comparing it with the EQ-5D-5L quality of life scale. Differences in scores between early-stage CKD patients and those on hemodialysis were used to test known-groups validity. Reliability was measured through internal consistency (Cronbach's alpha) and a two-week test-retest method.

Results: Of the 225 patients invited, 190 (84.4%) completed the survey. The content validity index (CVI) ranged from 0.73 to 1.00 across items. Exploratory factor analysis revealed factor loadings between 0.501 and 0.872, supporting construct validity. Significant correlations between the KDQOL-SF™ v1.3 domain scores and EQ-5D-5L measures confirmed convergent validity. Known-groups validity was demonstrated by significantly lower scores in physical function, role-physical, mental health, general health, pain, and fatigue domains among hemodialysis patients compared to those with earlier-stage CKD ($p < 0.05$). Cronbach's alpha values ranged from 0.710 to 0.883 across domains, indicating good internal consistency, while test-retest reliability coefficients ranged from 0.702 to 0.852.

Conclusion: The Indonesian version of the KDQOL-SF™ v1.3 is a valid and reliable tool to measure quality of life in hemodialysis patients. It can be used in both clinical practice and research to support patient-centered care and track outcomes. Future research should look at how well the tool detects changes in health and whether it works for patients with other stages of CKD.

Keywords: cross-culture adaptation, validation, psychometric, quality of life, chronic kidney disease.

INTRODUCTION

Chronic kidney disease (CKD) is a growing global health burden, affecting more than 750 million individuals worldwide (1,2). According to data from the World Health Organization (WHO), approximately 10% of the global population lives with CKD, yet only a fraction—around 10%—survives without access to dialysis or transplantation (3). The situation is particularly critical in developing nations, where the prevalence of CKD in the general population reaches 14.3%, and among high-risk groups, it escalates to 36.1% (4). In Asia, disparities in healthcare infrastructure further exacerbate outcomes, with an estimated 2.9 million individuals requiring hemodialysis (HD) due to a 66% shortage in service availability.

Indonesia exemplifies these global trends. National data reveal a significant increase in CKD prevalence from 2.0% in 2013 to 3.8% in 2018 among individuals aged 15 years and older (5,6). Concurrently, the number of patients receiving HD has risen sharply, from 77,892 in 2017 to 132,142 in 2018, with West Java Province alone accounting for 33,828 patients—the highest in the country (Kementerian Kesehatan RI Badan Penelitian dan Pengembangan, 2018). These figures underscore the escalating demand for renal replacement therapy and the pressing need to address the multifaceted consequences of CKD.

Hemodialysis remains the predominant modality for renal replacement therapy, alleviating symptoms and prolonging life expectancy for patients with end-stage kidney disease (8). However, despite its clinical benefits, HD imposes substantial physical, psychological, social, and economic burdens. Patients often report higher levels of stress, anxiety, and resignation compared to those with other chronic conditions (9,10). Numerous studies have highlighted that biological, psychological, social, and cultural factors interplay to profoundly diminish the quality of life (QOL) of individuals undergoing dialysis (11,12). Compared to patients with diabetes or cancer, those receiving HD consistently report lower QOL, reflecting the relentless demands of treatment and its pervasive impact on daily living (13–16).

Although valid and reliable instruments exist to measure QOL among CKD patients globally, research on culturally adapted measures remains limited, particularly in Indonesia. Given

that perceptions of illness, healthcare expectations, and coping mechanisms are deeply influenced by sociocultural contexts, the direct application of international instruments without adaptation risks misrepresenting patients' lived experiences (17). Translation and cross-cultural adaptation processes are therefore essential to ensure that instruments are linguistically accurate, culturally appropriate, and psychometrically sound. In response to these challenges, the present study aims to adapt and validate the Kidney Disease Quality of Life Short Form version 1.3 (KDQOL-SF™ v1.3) for use among Indonesian hemodialysis patients. This effort seeks to provide a robust, culturally sensitive tool capable of accurately capturing the health-related QOL in this growing patient population.

Quality of life has become a central patient-reported outcome measure (PROM) in nephrology research and clinical practice (18). Broadly defined, QOL encompasses individuals' subjective evaluations of how their illness and its treatment impact their functioning and well-being across physical, psychological, and social domains (19). These perceptions are inherently shaped by cultural backgrounds, personal beliefs, aspirations, expectations, and specific life contexts (20).

Generic QOL assessments, such as the 12-Item Short Form Health Survey (SF-12) (21), the World Health Organization Quality of Life instrument (WHOQOL) (22), and the European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L) (23), offer valuable insights into general health status. However, their broad focus may limit sensitivity to disease-specific concerns, particularly in CKD populations where the treatment burden, dietary restrictions, and psychosocial challenges are unique and profound. To address this gap, condition-specific QOL measures have been developed, aiming to capture aspects of life most affected by specific diseases with greater granularity.

Several instruments have been designed to assess QOL specifically in CKD, including the Kidney Transplant Questionnaire (KTQ) (24,25), the Kidney Disease Questionnaire (KDQ) (24), and tools developed through studies such as the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) (26). However, many of these measures focus on particular CKD subpopulations, such as transplant recipients or pre-dialysis patients. The Kidney Disease Quality

of Life Short Form (KDQOL-SF™ v1.3) stands out as a comprehensive tool that integrates both a general core—the SF-12—and kidney disease-targeted scales (27). It addresses domains uniquely relevant to individuals living with kidney disease, such as the burden of kidney disease, symptoms/problems, and effects of kidney disease on daily life. Given its dual structure and extensive validation in international settings, KDQOL-SF™ v1.3 has been widely adopted in clinical and research contexts.

Despite its use among Indonesian kidney disease populations, formal cultural adaptation and validation studies of the KDQOL-SF™ v1.3 in the Indonesian context are lacking. Considering Indonesia's diverse linguistic, religious, and cultural landscape, such an adaptation is crucial to ensure the instrument's conceptual equivalence, relevance, and sensitivity. This study thus addresses a significant methodological gap by adapting and validating the KDQOL-SF™ v1.3 for Indonesian hemodialysis patients, supporting more accurate assessment of their quality of life and informing culturally competent care interventions.

METHODS

Study design

A cross-sectional validation study was conducted between April 2020 and July 2020 in West Java, Indonesia, involving a public hospital and a hemodialysis (HD) clinic.

Translation of English KDQOL-SF™ v1.3 instrument into Bahasa version

Cognitive interviewing, a back-translation technique, an expert panel, and forward translation are the four stages involved in translating a questionnaire (28). The tool was translated into Bahasa by two separate translators, both of whom held Ph.D. degrees from universities abroad. Next, a group of experts met to examine the forward translation and find solutions to any differences compared to prior versions or current ones. Aside from the original translator, the expert panel also included a nurse and someone knowledgeable with translating and developing instruments. The next stage was for two native Bahasa speakers who had not been involved in the previous procedures to independently do a backward translation. Finally, ten patients receiving HD (five males and five females, all 18

years or older) were subjected to cognitive questioning and pre-testing (28)

Validity

Content and Face validity

The translated questionnaire was evaluated for content validity, relevance, proper phrasing, and prioritise using the Content Validity Index (CVI) (29). Three haemodialysis clinicians (a nurse and a doctor) and three specialists with doctoral degrees in nursing were invited to review the Bahasa-translated questionnaire. Using a different scale that takes into account different levels of content appropriateness and importance, we were able to determine the following: 1-content that is inappropriate and should be deleted; 2-content or articles that raise doubts and require significant effort; 3-content within an acceptable range but requiring minimal work; and 4-items that are appropriate without change. By applying Aiken's V formula, we were able to determine the Content Validity Index (CVI) score (30). There is a range of 0 to 1.00 for the V value. A extremely high CVI is indicated by a value of 0.80.

Fifteen non-specialist community members volunteered to evaluate the test's face validity by reading and timing how long it took them to complete the questions.

Construct validity

Construct validity was assessed through exploratory factor analysis (EFA) using principal component analysis (PCA) with Promax oblique rotation (31)(32). Sampling adequacy was evaluated using the Kaiser-Meyer-Olkin (KMO) measure and Bartlett's Test of Sphericity. Factors with eigenvalues greater than 1 were retained, and a factor loading of ≥ 0.40 was considered acceptable (31)(32).

Convergent validity

The term "convergent validity" describes the degree of correlation and measurement agreement between many instruments for the same construct (33). To test the convergent validity, we took the average variance from each component that was at least 0.5 (34).

Discriminant Validity

Discriminant validity was confirmed if the square root of AVE for each construct exceeded its correlations with other constructs (35).

Concurrent validity

The results of the eight domain questions on the Indonesian KDQOL-SFTM v1.3 were found to

correlate with the corresponding five domain scores on the EQ-5D-5L and the visual analogue scale (VAS), demonstrating concurrent validity. The Pearson correlation coefficient was used to investigate the relationships.

Known-groups validity

Known-groups validity was tested by comparing quality of life (QOL) scores between two groups: patients undergoing hemodialysis and patients with CKD stages 1-3A. Based on previous research (37-39). Hence, in order to test the known-groups validity, two groups of participants were chosen. In comparison to patients with CKD stages 1-3A, we anticipated that haemodialysis patients would have a worse quality of life.

Participants

Individuals were considered for recruitment if they met the following criteria: they were 18 years or older, fluent in Indonesian, and had a minimum of six months of haemodialysis experience. No patient was permitted to take part if they had a history of mental or cognitive illness. Patients with chronic kidney disease (CKD) stages 1-3A were included in the sample if they were at least 18 years old, fluent in Indonesian, and their CKD stages were confirmed by medical records. We did not include patients who had a history of autoimmune diseases, cancer that was actively spreading, or any kind of mental or cognitive impairment. A 1:5 ratio was used to determine the components (40). which in turn determined the sample size. There are 37 items in the KDQOL-SFTM v1.3. Patients undergoing HD and 100 patients CKD stage 1-3 needed to have their numbers multiplied by five, for a total of 185 participants. Using easy sampling, participants were recruited.

Instruments

Demographic information such as participants' sex, age, marital status, level of education, profession, and duration of HD therapy was gathered using a baseline questionnaire.

The Indonesian kidney disease quality of life

The KDQOL-SFTM v1.3 survey, which Joshi VD created in 2010, is a streamlined adaptation of the original KDQOL. It has two primary parts: the general core and the disease-specific core. The instrument was constructed from each of its 37 parts. The overall health item is one out of eight subscales that make up the general health items. Energy and exhaustion, general health, social function, physical functioning, emotional

well-being, pain, and role physical are the eight sub-scales. A score of 0 indicates severe insufficiency, whereas a score of 5 indicates excellent health. As the scores rise, it becomes clear that both measures of quality of life have improved. Scores ranging from zero to one hundred were calculated using the methods described in the user handbook. A perfect score of 100 indicates the highest possible quality of life.

The Indonesian EQ-5D-5L

Among the five dimensions and five components that make up the EQ-5D-5L are mobility, self-care, daily activities, discomfort, and anxiety/depression (41). The Bahasa version of the instrument was also available. Each of the five questions had a 5-point Likert scale, where 1 meant a high quality of life and 5 meant a low one. A percentage scale from 0 to 100 was used to convert the scores. Patients are asked to score their health on a scale from 0 (worst-case scenario) to 100 (best-case method) using a visual analogue scale (VAS).

Data collection

Prior to data collection, the institutional board of the connected university granted ethical authorisation. The hospitals and HD clinics that were observed granted consent for the research. The researchers met with the manager and chief nurse to go over the study's goals, procedures, and ethical considerations. Research participants' identities were divulged to the researchers by the management and head nurse. They were subsequently approached by the researchers, who outlined the study's purpose and methodology. A formal informed consent form was presented to each participant who consented to participate. The participants were asked to fill out the entire questionnaire when the study began. The Indonesian KDQOL-SFTM v1.3 was administered again to participants after a two-week period.

Reliability

Reliability is defined as the extent to which a measurement is free from measurement error (44).

Internal consistency

To determine how well a test's components assess the same concept, researchers utilised Cronbach's alpha coefficient (44). If Cronbach's alpha is below 0.70, then the internal consistency is weak; if it is between 0.70 and 0.90, then it is good (45).

Test-retest

Results from both the first and second tests were analysed using the intra-class correlation coefficient (ICC). Results over 0.9 suggest a high level of confidence, 0.75-0.90 suggest a good level of reliability, 0.5-0.75 indicate a moderate level of assurance, and less than 0.5 suggests a low level of dependability (45).

Data analysis

Data were analyzed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). Data normality was assessed prior to analysis. Descriptive statistics (mean \pm standard deviation, frequencies, and percentages) were used to summarize participant characteristics.

EFA using PCA with Promax rotation was conducted to explore factor structure. Sampling

adequacy was evaluated with KMO (>0.60 acceptable) and Bartlett's Test ($p<0.05$ indicating factorability). One-sample independent t-tests assessed known-groups validity. Pearson correlation coefficients tested concurrent validity between KDQOL-SFTM v1.3 and EQ-5D-5L/VAS scores.

Ethical consideration

Ethical approval was obtained from the affiliated university's institutional review board. Hospital and clinic administrators provided site approvals. Researchers met with managers and chief nurses to explain study objectives, ethical considerations, and confidentiality protocols. Participant recruitment was conducted confidentially. Informed consent was obtained before data collection.

RESULTS

Table 1. Demographic characteristics (n=290)

	HD patients n=190 (%)	CKD patients n=100 (%)
Age, Mean \pm SD	51.87 \pm 19.33	54.22 \pm 17.56
Gender		
Male	104 (54.7)	56 (56.0)
Female	86 (45.3)	44 (44.0)
Education level		
Above the senior high school	98 (51.6)	45 (45.0)
Below senior high school	92 (48.4)	55 (55.0)
Marital status		
Married	154 (81.0)	76 (76.0)
Single	36 (19.0)	24 (24.0)
Working status		
Employed	57 (30.0)	43 (43.0)
Unemployed	133 (70.0)	67 (67.0)
Length of HD (months), Mean \pm SD	13.87 \pm 4.29	-

Note: CKD: chronic kidney disease; HD: hemodialysis.

Of the 225 eligible patients undergoing hemodialysis (HD), 190 (84.4%) consented to participate, while 100 out of 132 patients with chronic kidney disease (CKD) stages 1–3 (75.8%) agreed to take part. Table 1 presents the demographic characteristics of the participants. The mean age of HD patients was 51.87 years (SD = 19.33), while CKD patients had a mean age of 54.22 years (SD = 17.56). Males constituted a slight majority in both groups (54.7% and 56.0%, respectively). Educational attainment was relatively balanced, with 51.6% of HD patients and 45.0% of CKD patients having completed education above the senior high school level. Most participants were married (HD: 81.0%; CKD: 76.0%). In terms of employment, 30.0% of HD patients and 43.0% of CKD patients were employed. The mean duration of HD therapy was 13.87 months (SD = 4.29).

Content and face validity

The content validity of the Indonesian KDQOL-SF™ v1.3 was assessed using Aiken's V formula, yielding coefficient values ranging from 0.73 to 1.00, indicating satisfactory content relevance. A value of ≥ 0.7 was considered acceptable. Regarding face validity, all participants reported that the questionnaire items were clear, easy to comprehend, and directly aligned with the instrument's objectives. Each item demonstrated an effect size greater than 1.5, supporting the clarity and acceptability of the tool.

Construct validity

Table 2. Factor loadings of the eight sub-scales of the Indonesian KDQOL-SF™ v1.3

	Role Physi- cal	Physica l Functio ning	Emotio nal well- being	Gene ral healt h	Social functi on	Pai n	Role emotio nal	Energy/fa tigue	K M O	AV E
1. Vigorous activities		0.543							0.83 4	0.5 82
2. Moderate activities		0.621								
3. Lifting carrying groceries		0.607								
4. Climbing several flights of stairs		0.568								
5. Climbing one flight of stairs		0.716								
6. Bending, kneeling, stooping.		0.653								
7. Walking more than a mile		0.790								
8. Walking several blocks		0.700								
9. Walking one block		0.670								
10. Bathing or dressing yourself		0.567								
11. Cut down the amount of time on activities	0.852								0.88 6	0.6 17
12. Accomplish less than what you would have liked	0.872									
13. Were limited in the kind of activities	0.861									
14. Have difficulty performing activities	0.823									
15. Body pain during last four weeks						0.74 5			0.79 1	0.5 92
16. Did pain interfere with your work?						0.77 0				
17. How would you rate your health?				0.372					0.87 6	0.6 35
18. I get sick more accessible than other people.				0.539						
19. I am as healthy as anyone else.				0.674						
20. I expect my health to get worse.				0.489						
21. My health is excellent.				0.635						
22. Have you been a nervous person?			0.650						0.76 8	0.5 74

23. You felt so down that nothing could cheer you up.	0.764			
24. Have you felt calm & peaceful?	0.436			
25. Have you felt downhearted and blue?	0.581			
26. Have you been a happy person?	0.634			
27. Due to emotional problems...				
28. You had to cut down the amount of time on activities		0.775	0.83	0.6
			1	11
		0.826		
29. You accomplished less				
30. You could not do activities as carefully as usual.		0.687		
31. To what extent have your physical health & emotional problems...				
32. Interfered with your everyday social life	0.437		0.76	0.5
			6	48
33. Interfered with visiting friends, relatives	0.501			
		0.76	0.85	0.6
34. Did you feel full of pep?			3	70
		0.77		
35. Did you have a lot of energy?				
		0.65		
36. Did you feel worn out				
		0.66		
37. Did you feel tired				

KMO Kaiser-Meyer-Olkin test, AVE average variance extracted, CR composite reliability

Exploratory factor analysis (EFA) using Promax oblique rotation confirmed an eight-factor model consistent with the original instrument structure. The Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy was 0.834, indicating good factorability. Factor loadings ranged from 0.501 to 0.872 (Table 2). Although Item 17 ("How would you rate your health?") exhibited a lower loading (0.372), it was retained to preserve the original construct integrity. The average variance extracted (AVE) values for all domains exceeded 0.5, supporting convergent validity.

Convergent and Discriminant validity

For eight domains, the instrument demonstrated strong convergent validity, with average extracted variances over 0.5 (Table 2).

Good discriminant validity was demonstrated by the instrument. With a correlation coefficient of greater than 0.7, the items and subscales measuring physical role, physical functionality, pain, emotional role, and energy/fatigue were moderately correlated (Table 2).

Concurrent validity

Table 3. Correlation of each subscale of Indonesian KDQOL-SF™ v1.3 with the EQ-5D- 5

	Mobility	Self-care	Usual activities	Pain/discomfort	Anxiety/depression
Role physical	0.579**				
Physical functioning	0.465**	0.441**			
Pain	0.351*	0.412**	0.407**		
General health	0.501**	0.351*	0.301*	0.312*	

Emotional well-being	0.407**	0.432**	0.276*	0.465**	0.432**
Role emotional	0.411**	0.535**	0.389*	0.394**	0.354*
Social function	0.386*	0.376*	0.435**	0.405**	0.455**
Energy/fatigue	0.445**	0.411**	0.366*	0.422**	0.387*

Note: * $p < 0.05$; ** $p < 0.001$

Table 3 shows that there is a statistically significant relationship between the five EQ-5D-5L components and the eight domains of the Indonesian KDQOL-SF™ v1.3. A moderate degree of connection was found between the KDQOL-SF™ v1.3 and the EQ-5D-5L. The EQ-5D-5L and the EQ VAS were shown to be linked with the Indonesian KDQOL-SFTM v1.3, with correlations ranging from 0.276 to 0.579 and 0.315 to 0.381, respectively.

Known-groups validity

Table 4. Known-groups validity of the Indonesian KDQOL-SF™ v1.3

	Patients on HD	Patients with CKD (Stage 1-3)	Independent-t-test	
	Mean \pm SD	Mean \pm SD	t	P-value
Role physical	55.78 \pm 19.57	59.15 \pm 17.65	-5.43	< 0.001
Physical functioning	68.34 \pm 23.11	73.45 \pm 34.14	-4.98	< 0.001
Emotional well-being	66.39 \pm 20.05	68.65 \pm 23.25	-2.01	< 0.001
General health	48.51 \pm 15.22	51.43 \pm 23.74	-3.90	< 0.001
Social function	67.33 \pm 25.17	68.48 \pm 22.60	-0.45	0.351
Pain	70.20 \pm 33.66	76.77 \pm 36.09	-5.76	< 0.001
Role emotional	70.68 \pm 34.04	73.55 \pm 30.037	-2.81	0.678
Energy/fatigue	55.14 \pm 22.28	60.01 \pm 37.54	-4.19	< 0.001

Known-groups validity was evaluated by comparing KDQOL-SF™ v1.3 scores between patients undergoing HD and those with CKD stages 1-3 (Table 4). Independent t-tests revealed statistically significant lower scores among HD patients in role physical ($t = -5.43$, $p < 0.001$), physical functioning ($t = -4.98$, $p < 0.001$), emotional well-being ($t = -2.01$, $p < 0.001$), general health ($t = -3.90$, $p < 0.001$), pain ($t = -5.76$, $p < 0.001$), and energy/fatigue ($t = -4.19$, $p < 0.001$) domains. No significant differences were observed in the social function domain ($p = 0.351$) and role emotional domain ($p = 0.678$).

Reliability

Table 5. Reliability of the eight sub-scales of the Indonesian KDQOL-SF™ v1.3

	Cronbach alpha	Intra-class correlation
Role physical	0.779	0.834
Physical functioning	0.856	0.816
Emotional well-being	0.877	0.843
General health	0.748	0.801
Social function	0.725	0.779
Pain	0.716	0.702
Role emotional	0.883	0.852
Energy/fatigue	0.837	0.789

Internal consistency reliability was excellent, with a Cronbach's alpha coefficient of 0.776 for the overall instrument. Domain-specific Cronbach's alpha values ranged from 0.716 to 0.883 (Table 5), indicating satisfactory internal consistency. Test-retest reliability, assessed using the intra-class correlation coefficient (ICC), demonstrated moderate to excellent stability across domains (ICC range = 0.702–0.852), with all estimates exceeding the minimum acceptable threshold of 0.7.

DISCUSSION

The present study provides robust evidence supporting the use of the KDQOL-SFTM v1.3 as a valid and reliable instrument for assessing the quality of life (QoL) among hemodialysis patients in Indonesia. The findings indicate that the KDQOL-SFTM v1.3 demonstrated satisfactory internal consistency, as evidenced by Cronbach's alpha coefficients and intraclass correlation coefficients (ICC), and acceptable construct validity within this population. While the KDQOL-SFTM v1.3 has been widely validated across Western populations, its psychometric properties have only recently been explored in Southeast Asia (46–49). Our results contribute to filling this regional research gap.

Consistent with previous studies, including validations conducted among Greek (51) and Malay (52,53) populations, the exploratory factor analysis in this study confirmed the instrument's eight-factor structure. Substantial correlations among role physical, role emotional, and pain subscales were observed, suggesting coherent domain clustering, while other domains displayed moderate to strong factor loadings. This pattern indicates that the instrument effectively captures distinct but related dimensions of health-related QoL in Indonesian dialysis patients (54,55).

Moreover, the favorable correlations between general health ratings and the specific renal disease domains reinforce the instrument's construct validity. These findings align with the notion that patient-reported outcomes (PROs) provide essential insights into patient experiences, capturing both subjective satisfaction and perceived functional limitations. Given the increasing diversity of the hemodialysis population, instruments like the KDQOL-SFTM v1.3, which encompass a wide range of patient-relevant concerns, are critically important.

However, while the KDQOL-SFTM v1.3 demonstrated good psychometric performance, future studies should examine its cultural sensitivity and potential content gaps. Regular use of focus groups or cognitive interviews could enhance ongoing content validation and ensure that the instrument remains responsive to evolving patient needs in the Indonesian context. Additionally, further research should assess the KDQOL-SFTM v1.3's responsiveness to clinical changes over time, a key property for longitudinal patient monitoring.

Implication

The KDQOL-SFTM v1.3 offers nurses a valid and reliable tool to assess the quality of life of patients undergoing hemodialysis. Utilizing this instrument in routine clinical practice can help nurses identify domains where patients are experiencing significant burdens, enabling tailored interventions to alleviate symptoms, improve patient-centered care, and support shared decision-making processes. Incorporating QoL assessments into routine care practices fosters a holistic approach to chronic disease management, empowering patients to engage actively in their care. The KDQOL-SFTM v1.3 is an effective instrument for future nursing and clinical research focused on hemodialysis populations. Future studies should investigate associations between QoL domains and clinical variables such as nutritional status, dialysis adequacy, and comorbidities. Comparative studies between hemodialysis and peritoneal dialysis patients could further elucidate modality-specific differences in QoL outcomes. Additionally, cultural adaptation studies and psychometric evaluations across different Indonesian regions are necessary to ensure cultural equivalence and maintain the instrument's validity over time.

Limitation

This study has several notable limitations. First, the absence of clinical parameter data such as hemoglobin levels, nutritional status, comorbidities, and dialysis adequacy restricted the evaluation of associations between QoL scores and clinical outcomes. Blinded data collection, although intended to minimize bias, inadvertently limited the ability to explore these important relationships.

Second, logistical challenges prevented re-contacting participants for follow-up assessments, precluding evaluation of test-retest

reliability and limiting the assessment of temporal stability. Third, the use of convenience sampling, although pragmatic, reduces the generalizability of the findings to the broader hemodialysis population in Indonesia. Selection bias may have favored the inclusion of patients with better health literacy or more positive health perceptions.

Future studies should address these limitations by incorporating clinical data, employing random or stratified sampling strategies, and implementing longitudinal designs to better capture changes over time and strengthen causal inferences.

CONCLUSION

To our knowledge, this study represents the first large-scale evaluation of the KDQOL-SFTM v1.3 among Indonesian hemodialysis patients. The findings demonstrate that the KDQOL-SFTM v1.3 possesses satisfactory internal consistency, construct validity, and discriminatory ability within this population. As such, it is a suitable instrument for assessing the quality of life among patients undergoing hemodialysis in Indonesia. Further research is warranted to examine the tool's responsiveness to clinical changes and to validate its performance across different dialysis modalities and diverse regional populations.

Acknowledgment

The authors would like to sincerely thank the participating patients and the staff at the hemodialysis units involved in this study for their support and cooperation.

Funding

None

Author Contribution

NS : Conceptualization and Study Design, Writing – Original Draft, Writing – Review & Editing

FMS : Methodology, Formal Analysis, Writing – Review & Editing

DHCH : Data Curation, Writing – Review & Editing

UN : Methodology, Formal Analysis

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this study.

Data Availability Statement

The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request. Access to the data is subject to ethical considerations and institutional approval.

REFERENCES

1. Kassebaum NJ, Arora M, Barber RM, Brown J, Carter A, Casey DC, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet*. 2016;388(10053):1603–58.
2. Bikbov B, Perico N, Remuzzi G. Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study. *Nephron*. 2018;139(4):313–8.
3. Jain S, Mohammadi R, Wallace BC. An analysis of attention over clinical notes for predictive tasks. *arXiv preprint arXiv:190403244*. 2019;
4. Luycx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. *Bulletin of the World Health Organization*. 2018/04/20. 2018 Jun;96(6):414–422D.
5. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*. 2020 Feb;395(10225):709–33.
6. Kementerian Kesehatan RI Badan Penelitian dan Pengembangan. Hasil Utama Riset Kesehatan Dasar. Kementerian Kesehatan Republik Indonesia. 2018;1–100.
7. IRR. 9 th Report Of Indonesian Renal Registry 2016. 2018;1–46.
8. Queeley, G. L., & Campbell ES. Comparing Treatment Modalities for End-Stage Renal Disease: A Meta-Analysis. *American health & drug benefits*. 2018. p. 118–27.
9. D'Onofrio G, Simeoni M, Rizza P, Caroleo M, Capria M, Mazzitello G, et al. Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients. *Ren Fail*. 2017;39(1):45–53.

10. Taheri-Kharameh Z, Zamanian H, Montazeri A, Asgarian A, Esbiri R. Negative religious coping, positive religious coping, and quality of life among hemodialysis patients. *Nephrourol Mon.* 2016;8(6):1-5.
11. Teles F, Amorim de Albuquerque AL, Freitas Guedes Lins IK, Carvalho Medrado P, Falcão Pedrosa Costa A. Quality of life and depression in haemodialysis patients. *Psychology, Health and Medicine.* 2018;23(9):1069-78.
12. Ganu VJ, Boima V, Adjei DN, Yendork JS, Dey ID, Yorke E, et al. Depression and quality of life in patients on long term hemodialysis at a national hospital in Ghana: a cross-sectional study. *Ghana medical journal.* 2018;52(1):22-8.
13. Bonenkamp AA, van Eck van der Sluijs A, Hoekstra T, Verhaar MC, van Ittersum FJ, Abrahams AC, et al. Health-Related Quality of Life in Home Dialysis Patients Compared to In-Center Hemodialysis Patients: A Systematic Review and Meta-analysis. *Kidney Medicine.* 2020;2(2):139-54.
14. Dąbrowska-Bender M, Dykowska G, Żuk W, Milewska M, Staniszevska A. The impact on quality of life of dialysis patients with renal insufficiency. *Patient preference and adherence.* 2018 Apr;12:577-83.
15. Kitagawa M, Sada K ei, Hinamoto N, Kimachi M, Yamamoto Y, Onishi Y, et al. Shorter dialysis session length was not associated with lower mental health and physical functioning in elderly hemodialysis patients: Results from the Japan Dialysis Outcome and Practice Patterns Study (JDOPPS). *PLoS ONE.* 2017;12(9):1-11.
16. Kim K, Kang GW, Woo J. The Quality of Life of Hemodialysis Patients Is Affected Not Only by Medical but also Psychosocial Factors: a Canonical Correlation Study. *Journal of Korean medical science.* 2018 Apr;33(14):e111-e111.
17. Arafat SY, Chowdhury HR, Qusar M, Hafez MA. Cross cultural adaptation and psychometric validation of research instruments: a methodological review. *J Behav Health.* 2016;5(3):129-36.
18. Ju A, Tong A. Considerations and challenges in selecting patient-reported outcome measures for clinical trials in nephrology. *Clinical Journal of the American Society of Nephrology.* 2017;12(11):1882-4.
19. WHO. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. *Psychological medicine.* 1998 May;28(3):551-8.
20. Hastuti P, Rahmawati I. Pengaruh Penyuluhan Tentang SADARI Terhadap Peningkatan Pengetahuan Pada Ibu-Ibu Kader Kesehatan Di Dusun Bangmalang Pendowoharjo Sewon Bantul. *Jurnal Kebidanan Khatulistiwa.* 2020;6(2):56-65.
21. Stewart A, Ware JE. Duke University Press. 1992. Measuring Functioning and Well-Being The Medical Outcomes Study Approach.
22. WHOQOL. WHOQOL: Measuring Quality of Life. 2004.
23. EuroQOL Group. EQ-5D-5L. 2009.
24. Laupacis A, Muirhead N, Keown P, Wong C. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. *Nephron.* 1992;60(3):302-6.
25. Laupacis A, Pus N, Muirhead N, Wong C, Ferguson B, Keown P. Disease-specific questionnaire for patients with a renal transplant. *Nephron.* 1993;64(2):226-31.
26. Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT. Physical symptoms and quality of life in patients on chronic dialysis: results of The Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD). *Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association.* 1999 May;14(5):1163-70.
27. Kalantar-Zadeh K, Unruh M. Health related quality of life in patients with chronic kidney disease. *International urology and nephrology.* 2005;37(2):367-78.
28. IDAI. Kurva pertumbuhan WHO [sitasi 20 September 2016]. . 2016.
29. Wood MJJRK. Basic Steps in Planning Nursing Research: From Question to Proposal: From Question to Proposal 7th Edition. Jones and Bartlett Publishing; 2011.
30. Azwar S. Reliabilitas dan Validitas. 4th ed. Yogyakarta: Pustaka Pelajar; 2015. 93-170 p.

31. DeVellis RF, Thorpe CT. Scale development: Theory and applications. Sage publications; 2021.
32. Mokkink L, Prinsen C, Bouter L, De Vet H, Terwee C. The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) and how to select an outcome measurement instrument. *Brazilian Journal of Physical Therapy*. 2016 Jan;20.
33. Cunningham WA, Preacher KJ, Banaji MR. Implicit attitude measures: consistency, stability, and convergent validity. *Psychological science*. 2001 Mar;12(2):163–70.
34. Fornell C, Larcker DF. Evaluating structural equation models with unobservable variables and measurement error. *Journal of Marketing Research*. 1981;18(1):39–50.
35. Fornell C, Larcker DF. Evaluating structural equation models with unobservable variables and measurement error. *Journal of Marketing Research*. 1981;18(1):39–50.
36. Davidson M. Known-Groups Validity BT - Encyclopedia of Quality of Life and Well-Being Research. In: Michalos AC, editor. Dordrecht: Springer Netherlands; 2014. p. 3481–2.
37. Manavalan M, Majumdar A, Harichandra Kumar KT, Priyamvada PS. Assessment of health-related quality of life and its determinants in patients with chronic kidney disease. *Indian journal of nephrology*. 2017;27(1):37–43.
38. Mujais SK, Story K, Brouillette J, Takano T, Soroka S, Franek C, et al. Health-related quality of life in CKD Patients: correlates and evolution over time. *Clinical journal of the American Society of Nephrology : CJASN*. 2009 Aug;4(8):1293–301.
39. Pagels AA, Söderkvist BK, Medin C, Hylander B, Heiwe S. Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment. *Health and quality of life outcomes*. 2012 Jun;10:71.
40. Osborne J, Costello AB. Sample size and subject to item ratio in principal components analysis. *Prac Assess Res Eval*. 2004 Jan;9.
41. Fermont J, Blazeby J, Rogers C, Wordsworth S. The EQ-5D-5L is a valid approach to measure health related quality of life in patients undergoing bariatric surgery. *PLOS ONE*. 2017 Dec;12:e0189190.
42. Costello AB, Osborne J. Best practices in exploratory factor analysis: Four recommendations for getting the most from your analysis. *Practical assessment, research, and evaluation*. 2005;10(1).
43. Hair JF, Black B, Babin BJ, Anderson RE. *Multivariate Data Analysis: Global Edition*, 7th Edition. Pearson education limited; 2014.
44. Mokkink L, Prinsen C, Bouter L, De Vet H, Terwee C. The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) and how to select an outcome measurement instrument. *Braz J Phys Ther*. 2016 Jan;20.
45. Jensen MP. Questionnaire validation: a brief guide for readers of the research literature. *The Clinical journal of pain*. 2003;19(6):345–52.
46. Chen JY, Choi EPH, Wan EYF, Chan AKC, Tsang JPY, Chan KHY, et al. Validation of the Disease-Specific Components of the Kidney Disease Quality of Life-36 (KDQOL-36) in Chinese Patients Undergoing Maintenance Dialysis. *PloS one*. 2016;11(5):e0155188.
47. Chao S, Yen M, Lin TC, Sung JM, Wang MC, Hung SY. Psychometric Properties of the Kidney Disease Quality of Life-36 Questionnaire (KDQOL-36™). *Western journal of nursing research*. 2016 Aug;38(8):1067–82.
48. Chow SKY, Tam BML. Is the kidney disease quality of life-36 (KDQOL-36) a valid instrument for Chinese dialysis patients? *BMC nephrology*. 2014 Dec;15:199.
49. Yang F, Griva K, Lau T, Vathsala A, Lee E, Ng HJ, et al. Health-related quality of life of Asian patients with end-stage renal disease (ESRD) in Singapore. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2015 Sep;24(9):2163–71.
50. Frost MH, Reeve BB, Liepa AM, Stauffer JW, Hays RD. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. 2007;10 Suppl 2:S94–105.

51. Park HJ, Kim S, Yong JS, Han SS, Yang DH, Meguro M, et al. Reliability and validity of the Korean version of Kidney Disease Quality of Life instrument (KDQOL-SF). *The Tohoku journal of experimental medicine*. 2007 Apr;211(4):321–9.
52. Goh SL, Persson MSM, Stocks J, Hou Y, Welton NJ, Lin J, et al. Relative Efficacy of Different Exercises for Pain, Function, Performance and Quality of Life in Knee and Hip Osteoarthritis: Systematic Review and Network Meta-Analysis. *Sports medicine (Auckland, NZ)*. 2019 May;49(5):743–61.
53. Budhiana J, Melinda F, Dewi R, Yulianti M, Arsyi DN. Factors affecting the quality of life of patients with chronic renal failure undergoing hemodialysis at RSUD Sekarwangi Sukabumi District. *Jurnal Keperawatan Komprehensif*. 2024;10(2)
54. Agustiyowati THR, Endah DR, Putri TARK. The Effect of Murottal Al-Quran Therapy on Anxiety Level of Chronic Kidney Disease Patients Undergoing Hemodialysis. *Jurnal Keperawatan Komprehensif (Comprehensive Nursing Journal)*. 2022;8(4).
55. Mochartini T. Determinant of Overload Occurrence in Clients Chronic Kidney Failure with Hemodialysis. *Jurnal Keperawatan Komprehensif (Comprehensive Nursing Journal)*. 2023;9(SpecialEdition).